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ABSTRACT
Purpose: To confirm a previous report of metastasis enhancement by lithotripter shockwaves (LSW) and to
test the hypothesis that this effect is attributable to cavitation.
Materials and Methods: The metastatic B16-D5 melanoma cell line was implanted on the hind legs of female
C57/b16 mice 12 days before tumor treatment. The tumors were treated with 500 LSW in a waterbath arrange-
ment. The effect of augmented cavitation nucleation was tested by intratumor injection of air bubbles or ul-
trasound contrast agent gas bodies (UCAGB). The primary tumor was surgically removed on day 1 after
treatment. The six groups of mice were sham, LSW, sham  air bubbles, LSW  air bubbles, sham 
UCAGB, and LSW  UCAGB. Data were collected for the 113 mice that survived at least 25 days. Lung eval-
uations were performed blind after 2 weeks of bleaching in Fekete’s solution.
Results: The outcomes of the three sham groups were very similar and indicated that the simple injection
of material into the tumor did not increase metastasis. In comparison with the pooled shams, both the LSW 
air bubbles and LSW  UCAGB groups had statistically significant increases in metastasis counts. Only the
LSW  UCAGB group had a significant increase in incidence of metastasis relative to the pooled shams. The
LSW  UCAGB also had significantly reduced survival.
Conclusion: Shockwaves can enhance metastasis from tumors, and this effect is attributable to cavitation.
INTRODUCTION
LITHOTRIPTER SHOCKWAVES (LSW) have a broad po-tential for nonthermal biologic effects.1,2 These can occur
directly, as in stress fractures of kidney stones, or indirectly,
via the cavitation mechanism. Cavitation appears to be respon-
sible for adverse side effects of shockwave lithotripsy, and these
can be reduced by treatment modifications that reduce cavita-
tion.3 The broad potential for nonthermal bioeffects has led to
research on the use of LSW for therapeutic applications other
than stone disease.
An initially promising application was to cancer therapy.
Shockwaves have been shown to have a strong antitumor ef-
fect either alone4,5 or in combination with other measures such
as chemotherapy6,7 or gene therapy.8 One reported adverse ef-
fect of this treatment is a tendency for an increase in metasta-
sis with treatment of highly malignant tumors.9 Other shock-
wave tumor treatment studies have not reported increased
metastasis, although these studies were not specifically de-
signed to search for metastases.
The goals of the present study were to confirm the report of
metastasis enhancement9 in a different tumor model and to test
the hypothesis that this effect is attributable to cavitation. The
highly metastatic D5 melanoma cell line was used, which
metastasizes to the lung in vivo. Tumor treatment was conducted
with LSW alone or with augmentation of cavitation activity by
intratumor injection of cavitation nuclei, which we have found
to be important for reliable cavitation nucleation in vivo.10 The
results demonstrate enhancement of metastasis by shockwave
cavitation.
MATERIALS AND METHODS
All animal research was conducted with the approval of the
University Committee for the Use and Care of Animals and the
Department of Radiology, University of Michigan Medical Center, Ann Arbor, Michigan.
guidance of the Unit for Laboratory Animal Medicine of the
University of Michigan. For this study, the highly metastatic
B16-D5 melanoma cell line was used with female C57/b16
mice. These cells form visible lung metastases about 18 days
after tail vein injection and also will grow as subcutaneous (SQ)
tumors (as for the B16 melanoma model). The experimental
plan utilized established methods to test for enhanced lung me-
tastasis resulting from therapeutic or diagnostic manipulation
of tumors implanted on the hind leg.9,11–13 A suspension of 2
million cells in 0.1 mL was injected SQ on the right hind leg
of each mouse under ether anesthesia. Treatment was applied
after 12 days of tumor growth.
For treatment, mice were weighed (averaging 21  1.2 g)
and anesthetized with an intraperitoneal injection of ketamine
75 mg/kg (Ketaset; Aveco Co., Fort Dodge, IA) and xylazine
15 mg/kg (Rompun; Mobay Corp., Shawnee, KS). The tumor
area was shaved and depilated, and the volume of each tumor
was estimated using digital calipers to measure the three major
axes and calculating the ellipsoidal volume, which averaged
302  118 L. In one third of the mice, a volume of air equal
to 10% of the tumor volume was mixed by hand agitation with
an equal volume of saline to form an air bubble suspension, and
this was injected into the tumor (IT) with a 28-gauge needle
one time approximately 5 minutes prior to LSW treatment. Al-
ternatively, one third of the mice receive an injection of Opti-
son® ultrasound contrast medium at 10% of tumor volume, the
contrast being gently mixed with saline and injected in the same
way. The air bubbles and the ultrasound contrast agent gas bod-
ies (UCAGB) served as cavitation nuclei, as described previ-
ously.10,14 Optison® was purchased from Amersham Health Inc.
(Princeton, NJ). According to the package insert, this agent con-
tains 500 to 800  106 perfluoropropane gas bodies per milli-
liter with a mean diameter of 2 to 4.5 m. After resuspension,
the agent was withdrawn from the sealed vial using an Op-
tispike™ dispensing pin. A fresh vial was used each treatment
day. The anesthetized mouse was mounted on a plastic board,
which incorporated a 2.0-cm beam hole surrounded by a foam-
plastic shield. This mounting was arranged to center the tumor
in the beam hole and then placed in a 37°C waterbath for ex-
posure as described previously.10 After LSW treatment, the
mice were removed from the bath, dried, and allowed to re-
cover in warmed chambers before return to regular cages.
A laboratory LSW system, which was similar to a Dornier
HM3 lithotripter and fitted with standard spark gaps (Dornier
Medical Systems, Kennesaw, GA), was used for treatment as
described previously.10 Briefly, the water in the exposure bath
was degassed for 1 hour by vacuum prior to filling of the bath
and then continuously filtered to minimize the occurrence of
cavitation. The LSW output was measured at the focus, 12 cm
from the mouth of the reflector, and the main pulse had a spa-
tial peak pressure amplitude of 42.6  1.4 MPa peak positive
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TABLE 1. OVERALL OUTCOME FOR TREATMENT GROUPS
Tumor 25-day 42-day
Total Treatment Surgery recurrence survival survival
Sham 19 0 0 2 19 11
LSW 21 1 2 5 18 13
Sham  air bubbles 21 1 0 0 20 13
LSW  air bubbles 21 1 0 7 20 9
SHAM  UCAGB 20 0 0 3 20 12
LSW  UCAGB 24 7.a 1 3 16 3
ap  0.5 relative to sham  UCAGB.
Died 4 d
FIG. 1. Mouse lungs after (A) sham  UCAGB and (B) 500
LSW  UCAGB. Dark spots, which appear mostly near sur-
face of lungs in panel B, are melanoma metastases, which were
scored as zero in (A) and 13 in (B).
and 7.4  1.9 MPa peak negative. For tumor treatment, 500
LSW were delivered at a 2-Hz rate.
After treatment, sufficient time must be allowed for any cells
metastasizing to the lungs to grow into tumors of visible size.
To permit prolonged survival, the primary tumor was surgically
removed the day after treatment. If the primary tumor is not
surgically removed, it will continue to grow and kill the mice
within about 10 days, which is too brief a time to allow for-
mation of visible lung metastases. After the mice were reanes-
thetized, excision was accomplished by removal of the leg at
the hip and suture of the skin over the area. Recovery was aided
by injection of 1 mL of warm saline intraperitoneally, together
with buprenorphine analgesic 0.1 mg/kg SQ.
The experimental plan was for 6 groups of 20 mice each, with
the overall outcome listed in Table 1. This moderately large group
size was needed for statistical validity, owing to the background
metastasis rate. The groups were sham, LSW, sham  air bub-
bles, LSW  air bubbles, sham  UCAGB, and LSW 
UCAGB. Mice were treated on each of 2 days per week for 6
weeks. Normally, one or two extra mice were available each day
to replace mice that failed to grow injectable tumors or died at
the time of treatment. On one treatment day, only nine mice were
available, and a sham exposure was omitted from the study. A to-
tal of 126 mice were treated. Ten mice died within 1 day of treat-
ment, which was attributed to the exposure procedure. Three other
mice died of complications from the surgery. The mice were eu-
thanized if a tumor recurred and reached 3000 L in volume or
at 42 days after treatment. Data were collected for the 113 mice
that survived at least 25 days. For evaluation, the lungs were re-
moved and bleached in Fekete’s solution to count the pigmented
lung metastases.12 The metastatic nodules were evaluated blind
after 2 weeks in the Fekete’s solution by examination under a low-
power stereo microscope. Figure 1 shows the gross lung pho-
tographs from a sham  UCAGB mouse and from an LSW 
UCAGB mouse. Statistical comparisons of the mean metastases
counts were made using the Mann-Whitney rank sum test, and
the occurrence rates were compared using the z test (SigmaStat
2.0; SPSS Inc., Chicago, IL).
RESULTS
The D5 melanoma proved to be highly metastatic, with a
lung metastasis rate of 53% in sham-treated animals, and a re-
currence rate of the primary tumor of 16% at the site of the sur-
gery (Table 2). The results in the three sham groups were very
similar and indicate that the simple injection of material into
the tumor did not increase metastasis. For comparison between
sham and treated groups, only the LSW  UCAGB group had
a statistically significant increase in metastases (Fig. 2). In com-
parison with the pooled shams, both the air bubbles  LSW
and LSW  UCAGB groups had statistically significant in-
creases in metastasis counts, but only the LSW  UCAGB
group had a significant increase in the occurrence of metasta-
sis relative to the pooled shams.
The biologic effects generated by the LSW  UCAGB in-
cluded reduced survival. Only 3 of the 23 animals in this group
survived to the 42-day cut-off, and 7 died soon after the treat-
ment (i.e., within 1 day) (see Table 1). The high early death
rate (7 of 23), which was apparently attributable to the treat-
ment, was significantly increased relative to the sham 
UCAGB group (0 of 20) (P  0.024) and to the pooled shams
(1 of 60) (P  0.005).
DISCUSSION
The goals of this study were to confirm the report of an en-
hancement of metastasis for LSW tumor treatment,9 and to test
the hypothesis that the effect is attributable to cavitation. The
shockwave treatment by itself produced a nonsignificant in-
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TABLE 2. LUNG METASTASIS OCCURRENCE AND COUNTS IN MICE SURVIVING AT LEAST 25 DAYS
25-day No. with metastasis Metastases
survival (%) count (SEM) Group Pooled
Sham 19 10 (53) 1.7 (0.7) 0.77 0.93LSW 18 9 (50) 3.4 (1.2)
Sham  air bubbles 20 11 (55) 2.5 (0.7) 0.24 0.046LSW  air bubbles 20 15 (75) 3.5 (0.8)
SHAM  UCAGB 20 12 (60) 2.0 (0.8)
0.001 0.001LSW  UCAGB 16 15 (94)a 8.2 (1.2)
ap  0.05 relative to pooled shams (i.e., 33 of 59 or 55%).
Count p values
FIG. 2. Comparison of mean lung metastasis count for each
group with standard error bar. Fractional number of mice sur-
viving at least 25 days with lung metastasis is shown above
each bar.
crease in metastasis counts. The background count was rela-
tively high in this study, which reduces the power of this neg-
ative finding. With enhanced cavitation nucleation, a signifi-
cant increase in metastasis counts was found. This was
particularly strong for nucleation with UCAGB, which gave an
increase in the rate of metastasis occurrence. Therefore, al-
though the LSW alone failed to increase metastasis signifi-
cantly, the results should be considered a confirmation of the
positive report9: Treatment of tumors with LSW can increase
metastatic spread of cancer. The hypothesis that the metastasis
enhancement effect is attributable to cavitation was confirmed
in this study. Enhancing cavitation nucleation increased metas-
tasis, and the greater nucleation provided by the numerous gas
bodies in Optison was most efficacious compared with LSW or
LSW  air bubbles.
Only three mice appeared to succumb to complications of
the surgery. The survival was reduced in the LSW  UCAGB
group compared with other groups, apparently as a result of the
treatment. In this group, blood was usually visible under the
skin around the tumor after treatment, which suggests that hem-
orrhage contributed to the lethal effect. This agrees with previ-
ous findings of reduced survival of mice treated with IV-in-
jected contrast agent and LSW exposure to the abdomen15 and
with IV-injected contrast agent and LSW tumor treatment.10
The high rate of metastasis found in this study indicates a sub-
stantial release of tumor cells or debris into the circulation,
which may also contribute to the lethal effect (e.g., by pul-
monary embolism).
Both the metastasis enhancement effect and the lethality
result from LSW cavitation. Cavitation involves the growth
of giant cavities during and after the prolonged rarefactional
phase of the shockwave pulse,16,17 which can rupture 200-
m-diameter tubes.18 However, the vessel rupture leading to
hemorrhage and metastasis need not originate in the blood.
Previous work has shown that cavitation bubbles can be im-
aged in shockwave-exposed tissue above a threshold of only
1.5 to 3.5 MPa.19 In contrast, bubbles were not detected in
circulating blood for full-amplitude LSW (10 MPa) ow-
ing to the continuous filtering in vivo, which depletes cavi-
tation nuclei in blood.20 In this present work, the nuclei were
injected into the tumor tissue (rather than the blood) and were
effective in inducing hemorrhage and enhancing metastasis.
Thus, it seems likely that the nucleation of cavitation giving
the adverse consequences of LSW occurs primarily in the tis-
sue interstitium.
CONCLUSION
Lithotripter shockwaves can enhance metastasis from tu-
mors, and this effect is attributable to the cavitation mech-
anism. The particularly strong effects induced by the pres-
ence of UCAGB support a recommendation that lithotripsy
not be performed within 24 hours after ultrasound contrast
agent administration.21 Furthermore, given the findings of
metastasis enhancement, it appears that LSW should not
have a role in cancer therapy and should be avoided in pa-
tients with malignancy within the lithotripsy-treatment vol-
ume.
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